Servier

Servier and Oncodesign announce Parkinson’s R&D tie-up
Servier and Oncodesign announce Parkinson’s R&D tie-up
Pharmaforum
Servier
Oncodesign
R&D
Parkinson's Disease
Flag link:
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Pharmaceutical Business Review
Amgen
heart failure with reduced ejection fraction
Omecamtiv Mecarbil
Cytokinetics
Servier
Flag link:
FDA approves Servier's ALL therapy, acquired in Shire deal
FDA approves Servier's ALL therapy, acquired in Shire deal
BioCentury
FDA
SHP663
Servier
ALL
Flag link:
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Fierce Biotech
Servier
GeNeuro
MS
multiple sclerosis
GNbAC1
Flag link:
Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
CP Wire
Servier
Taiho Pharmaceutical
Lonsurf
gastric cancer
Flag link:
Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
Servier
Taiho Pharmaceutical
Lonsurf
gastric cancer
Flag link:
Servier opens Kendall Square site, plans Chinese office to access external innovation
Servier opens Kendall Square site, plans Chinese office to access external innovation
Fierce Biotech
Servier
Kendall Square
Boston
Biogen
R&D
Flag link:
Shire's oncology exit weighs on potential Takeda bid
Shire's oncology exit weighs on potential Takeda bid
Biopharma Dive
Shire
oncology
Takeda
M&A
Servier
Flag link:
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Endpoints
Servier
Shire
Takeda
M&A
oncology
Flag link:
Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis
Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis
Endpoints
Pfizer
Servier
FDA
CAR-T
UCART19
Cellectis
acute lymphocytic leukemia
Flag link:
Servier Joins Hands With Intarcia Therapeutics To Develop Implantable Diabetic Pump
Servier Joins Hands With Intarcia Therapeutics To Develop Implantable Diabetic Pump
Bidness Etc.
Servier
Intarcia
diabetes
devices
Flag link:
Pharmacyclics, Servier call it quits on a cancer drug
Pharmacyclics, Servier call it quits on a cancer drug
Fierce Biotech
Pharmacyclics
Servier
Abexinostat
Flag link:
SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug
SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug
Forbes
clinical trials
Amgen
SIGNIFY
Servier
Procoralan
Corlentor
Flag link:
Servier to Teva Fined $582.2 Million on Generic Delays
Servier to Teva Fined $582.2 Million on Generic Delays
Bloomberg
Servier
Teva Pharmaceutical
generics
perindopril
Flag link:
Galapagos inks $367M deal in back-ended discovery pact with Servier
Galapagos inks $367M deal in back-ended discovery pact with Servier
Fierce Biotech
Servier
Galapagos
Flag link:
Servier Denies Concealing Risk Of Diabetes Drug
Servier Denies Concealing Risk Of Diabetes Drug
Pharmalot
diabetes
Servier
Mediator
Flag link: